DBVT opened at $6.20 on Friday. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $8.32. The stock has a market capitalization of $127.53 million, a P/E ratio of -1.38 and a beta ...

Clinical-stage biopharmaceutical company DBV Technologies (NASDAQ:DBVT) announced a financing of up to $306.9M (€284.5M), including gross proceeds of $125.5M (€116.3M) to be received upon ...

DBV Technologies secured up to $306.9M to advance its Viaskin Peanut program. The funding supports FDA submission, commercialization and ongoing pediatric peanut allergy treatment research. Learn ...

Shares of DBV Technologies (DBVT) are moving lower after the company a “substantial doubt regarding its ability to continue as a going concern.” When reporting unaudited results for 2024 ...

American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million. The biopharmaceutical company's ADRs were up 57%, at $6.14, Friday morning.

DBV Technologies' American depositary receipts fell after the company said its cash would likely run out after next month. The stock was down 10% at $4.48 in premarket trading on Monday. Shares ...

Shares of DBVT stock opened at $4.99 on Friday. The firm has a market cap of $102.64 million, a P/E ratio of -1.11 and a beta of 0.71. DBV Technologies has a fifty-two week low of $2.20 and a ...

Investing.com -- DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, experienced a 10% drop in its American depositary receipts, trading at $4.48 in premarket trading on ...

General Assembly's unanimous vote on Thursday followed a recommendation from the IOC executive board, which had provisionally recognized World Boxing as the sport's governing body in February. Michael ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...